Premium
Comparison of hydroxyapatite and beta tricalcium phosphate as bone substitutes after excision of bone tumors
Author(s) -
Ogose Akira,
Hotta Tetsuo,
Kawashima Hiroyuki,
Kondo Naoki,
Gu Wenguang,
Kamura Takeshi,
Endo Naoto
Publication year - 2004
Publication title -
journal of biomedical materials research part b: applied biomaterials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.665
H-Index - 108
eISSN - 1552-4981
pISSN - 1552-4973
DOI - 10.1002/jbm.b.30136
Subject(s) - radiodensity , curettage , deformity , medicine , artificial bone , surgery , radiography , biomedical engineering
Long‐term results are reported in 23 patients and short‐term results in 30 patients presenting with bone tumors treated by curettage or resection followed by implantation of hydroxyapatite (HA) or highly purified beta‐tricalcium phosphate (β‐TCP), respectively. Mean follow‐up was 97 and 26 months in cases involving HA implantation and β‐TCP implantation, respectively. Radiographs revealed HA incorporation into host bone in all but two cases; moreover, no obvious evidence of HA biodegradation was observed. A single patient exhibited late deformity following implantation of HA. All grafted β‐TCP was, at least partially, absorbed and replaced by newly formed bone. The mean period required for the disappearance of radiolucent zones between the ceramics and host bone was 17 weeks in HA and 9.7 weeks in β‐TCP. Highly purified β‐TCP appears to be advantageous relative to HA for surgical intervention in bone tumors consequent to the nature of remodeling and superior osteoconductivity. © 2004 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 72B: 94–101, 2005